Aerie Pharmaceuticals
Aerie Pharmaceuticals Inc. (NASDAQ: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daily IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension.[1][2][3]
| Type | Publicly traded |
|---|---|
| NASDAQ: AERI Russell 2000 Component | |
| Industry | pharmaceutical companies |
| Website | aeriepharma |
References
- Witkowski, Wallace (16 September 2015). "Aerie Pharma Shares Skyrocket On Glaucoma Drug Study Results". Fox Business.
- Beckerman, Josh. "Aerie Pharmaceuticals Shares Rise on Trial Results". Wall Street Journal.
- "Aerie Pharma shares battered as eye drug fails study". Reuters. 23 April 2015. Retrieved 7 January 2016.
External links
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.